December 2025 - Page 9 of 10

Release – Kratos Opens New 10,000 Sq Ft Facility for Engine Overhaul Business in British Colombia

Posted on December 5, 2025December 5, 2025 by aweinsoff@channelchek.com

December 5, 2025

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leader in defense, national security and global markets, today announced the opening of its new state‑of‑the‑art 10,000 square foot facility for PT6A and PT6T engine overhaul in Vancouver, British Colombia—a significant milestone in the company’s continued growth and innovative support of the PT6A and PT6T engine market. This modern space has been designed to enhance operational efficiency, foster collaboration, and provide the infrastructure needed to meet the evolving demands of the industry. The expansion underscores Kratos’ commitment to delivering cutting‑edge solutions and ensuring that its teams have the resources required to drive excellence across all areas of operation.

Kratos MRO Canada

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c11db7da-a974-40f8-91f2-635ac42662dd

The new facility also strengthens Kratos’ Bristow, Oklahoma operations, enabling expanded capabilities and improved service delivery for Canadian operators. By investing in advanced technology and increased capacity, Kratos’ Consolidated Turbines divisions in Canada and Oklahoma are better positioned to support its partners with greater responsiveness, reliability, and scalability. This move reflects the company’s dedication to building strong international relationships and providing unmatched support to operators across North America, reinforcing its role as a trusted leader in the PT6T and PT6A industry.

“This move will create seemingly endless possibilities with regards to expansion, employment and in-house capabilities. We are fortunate to have many long-standing Bell Medium customers in Canada, which operate the PT6T model engines. Our goal is to add the fixed wing version (PT6A models) to our quiver in the near future,” said Dave Wark, Director of Kratos MRO Canada.

Kratos MRO Canada’s New Facility

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/30d7c652-f958-4302-a1b9-d782e597794d

CTS Canada started 20 years ago to support PT6 maintenance, repair, and overhaul in Langley, BC. Now a Kratos business, the company has grown significantly with its third expansion in less than ten years that provides the opportunity to support customers better than ever before, a testament to Kratos’ great team that works tirelessly to keep customers flying.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, advanced vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Kratos MRO Canada

Kratos MRO Canada

Kratos MRO Canada’s New Facility

Kratos MRO Canada’s New Facility

Source: Kratos Defense & Security Solutions, Inc.

Netflix’s $72 Billion Warner Bros. Deal Reshapes Hollywood — and Sends Ripples Through the Small & Micro-Cap Media Space

Posted on December 5, 2025December 5, 2025 by slightbourne@noblecapitalmarkets.com

Netflix’s landmark $72 billion acquisition of Warner Bros.’ studios and HBO Max marks one of the most transformative moments in modern entertainment history — a move that not only reshapes Hollywood’s power structure but also sends meaningful ripple effects through the small- and micro-cap media and technology ecosystem.

Announced Friday, the agreement gives Netflix control of Warner Bros.’ iconic film and TV library, including franchises like Harry Potter, DC, The Sopranos, Game of Thrones, and Friends, along with the HBO Max streaming platform. The deal is expected to close following Warner Bros. Discovery’s plan to spin off its Global Networks division in 2026, creating a new publicly traded entity housing CNN and its linear cable assets.

The acquisition is historic for Netflix, a company that has primarily built its empire through original content rather than mergers. As of Q3, nearly two-thirds of its content library consists of originals, with no single show representing more than 1% of viewership. This diversification insulated Netflix from industry consolidation — but the streaming landscape has changed dramatically.

With HBO Max, Paramount+, and Peacock all struggling to scale, analysts widely believe only a handful of global players will survive. Securing Warner Bros.’ intellectual property may not just be strategic — it may be defensive, ensuring that no rival streaming service gains control of one of Hollywood’s deepest content vaults.

The Small & Micro-Cap Effect: Why This Deal Matters Down the Ladder

While mega-cap giants are the headline story, the implications for small and micro-cap entertainment, production, and streaming-adjacent companies could be significant.

This consolidation wave often results in:

• Increased demand for independent content:
As major studios merge, they frequently trim internal production pipelines. This opens opportunities for small-cap and micro-cap production houses, animation studios, and niche content creators that can sell or license projects to fill larger platforms’ volume needs.

• Rising valuations for niche streaming and IP owners:
Micro-streamers, genre-focused platforms, and specialty content IP holders often benefit from industry shakeups. With the “big three” fighting for subscriber retention, specialty libraries — from horror to anime to sports archives — tend to gain acquisition interest or licensing deals.

• Technology spillover:
Cloud providers, AI-driven media startups, captioning tech, localization companies, and compression software developers — many of which fall in the micro-cap category — may see increased demand as larger platforms race to integrate and scale newly combined content libraries.

• Greater pressure on small-cap competitors:
Independent media companies without premium IP or distribution scale could feel heightened pressure. Some may become acquisition targets; others may need to pivot toward niche verticals to remain competitive.

In essence, mega-mergers at the top often spark a wave of secondary deals at the bottom.

Regulatory Uncertainty Still Looms

Like other bidders, Netflix will face intense regulatory scrutiny given its global scale. Analysts note that Paramount would have had the cleanest approval path. Meanwhile, competitor pressure may persist — both Paramount and Comcast could re-engage or attempt to challenge the deal’s fairness.

Still, Netflix ultimately prevailed thanks to one key advantage: liquidity. The final agreement provides each WBD shareholder $23.25 in cash and $4.50 in Netflix stock, demonstrating Netflix’s willingness to pay up to secure long-term streaming dominance.

A New Era of Entertainment

If approved, the acquisition unites a century of Warner Bros. storytelling with the world’s largest streaming platform — a fusion that could define the next chapter of global content.

For small and micro-cap players, the message is clear: Another consolidation wave is here, and the companies able to adapt quickly — or strategically position themselves as acquisition targets — stand to benefit the most.

Century Lithium Corp. (CYDVF) – A New Dimension to Angel Island

Posted on December 5, 2025December 5, 2025 by slightbourne@noblecapitalmarkets.com

Friday, December 05, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Recovery of rare earth elements (REE). Century recovered rare earth elements from leach solutions generated from its Angel Island Lithium Project. Initial testing indicated that high rare earth element recoveries may be achieved without impacting lithium recovery. Producing a secondary REE-rich product from the leach solution offers the potential to enhance Angel Island’s project economics, while fulfilling broader government and industry objectives of promoting a North American critical mineral supply chain to reduce dependence on China.

The process works. Leach solutions produced from Angel Island claystone contain dysprosium, gadolinium, neodymium, and praseodymium, along with higher concentrations of scandium, lanthanum, and cerium. Ion-exchange achieved greater than 97% recovery of the identified REEs and critical metals, without affecting the company’s core lithium recovery process and production of high-purity lithium carbonate.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Release – Titan International Inc. Announces Executive Leadership Transitions Including New Role of Chief Transformation Officer to Accelerate Strategic Objectives

Posted on December 4, 2025December 22, 2025 by aweinsoff@channelchek.com

Research News and Market Data on TWI

Dec 4, 2025

WEST CHICAGO, Ill., Dec. 4, 2025 /PRNewswire/ — Titan International, Inc. (NYSE: TWI) (“Titan” or the “Company”), a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products, today announced a series of executive appointments designed to strengthen its leadership team and support the company’s long-term strategic objectives.

David Martin, previously Senior Vice President & Chief Financial Officer, has been appointed Senior Vice President and Chief Transformation Officer (SVP & CTO). In this newly created role, David Martin will lead enterprise-wide transformation initiatives focused on strategic alignment, operational agility, and long-term value creation. He will oversee the critical alignment of information technology, including acceleration of AI adoption, along with human capital, and risk management functions and initiatives. Over the last seven years, his leadership has been pivotal in repositioning Titan’s financial foundation to become a strength for future growth opportunities.

Tony Eheli, formerly Vice President and Chief Accounting Officer, has been appointed Senior Vice President and Chief Financial Officer (SVP & CFO). With a proven track record of financial leadership, strong governance, and driving performance improvements over the years, Tony Eheli has been responsible for Titan’s global financial reporting, audit oversight, and operational controls, as well as leadership of the North American operational finance organization. Prior to joining Titan, Tony Eheli served in several finance leadership roles at Danaher, and in roles of increasing responsibility at PwC. He brings strong financial discipline and will continue to be a strategic partner in driving Titan’s long-term growth and value creation.

Jim Pach, formerly Corporate Controller, has been appointed Vice President and Chief Accounting Officer (VP & CAO). Jim Pach brings expertise in financial compliance, reporting, and internal controls, and has played a key role in supporting Titan’s global finance operations for the last six years. His promotion reflects the company’s commitment to continuity and excellence in financial stewardship. Prior to joining Titan, Jim Pach worked in senior accounting roles at various public companies, and in roles of increasing responsibility at PwC.

These appointments are effective immediately.

“These leadership transitions reflect our confidence in the strength and depth of Titan’s executive team,” said Paul Reitz, President and CEO of Titan International. “David, Tony, and Jim have each demonstrated exceptional leadership and strategic insight for the business. Their new roles will increase bandwidth to accelerate achievement of our strategic objectives and deliver sustainable value to our shareholders.”

About Titan

Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products. Headquartered in West Chicago, Illinois, the Company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-international-inc-announces-executive-leadership-transitions-including-new-role-of-chief-transformation-officer-to-accelerate-strategic-objectives-302633545.html

SOURCE Titan International, Inc.

Release – SKYX Launches its Patented Ceiling Plug & Play SKYFAN & TURBO HEATER on its U.S. E-Commerce Platform

Posted on December 3, 2025December 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SKYX

December 03, 2025 09:12 ET | Source: SKYX Platforms Corp.

Driven by Strong Demand, the Company Expects Additional Winter Launches with Several Leading U.S. Retailers, Including Big-Box Chains

Management Expects the Turbo Heater & Ceiling Fan to Generate Significant Revenue Beginning this Winter and Continuing through Fiscal Year 2026

The Company Anticipates that the Winter Launch Will Help Advance its Path to Cash-Flow Positivity

Ceiling Fan and Space Heater Categories Represent a Multi-Billion-Dollar Annual Market, with Tens of Millions of Units Sold Each Year in the U.S.

MIAMI, Dec. 03, 2025 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 100 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced the launch of its newly patented all-in-one ceiling plug & play SKYFAN & TURBO HEATER on its U.S. e-commerce website platform.

The innovative product—combining a ceiling fan with a built-in turbo heater—offers a safer, more efficient alternative to traditional space heaters and addresses a large year-round market opportunity across both winter and summer seasons. The combined ceiling fan and portable heater category is a multi-billion-dollar market, with tens of millions of units sold annually in the U.S. alone.

In response to strong demand, SKYX will offer the product in six colors to serve both residential and commercial markets. Production is now underway with the Company’s manufacturing partners, and SKYX expects a broad rollout in Q4 2025 and Q1 2026 to align with the winter season.

Huey Long, CEO of SKYX’s eCommerce Platform Belami, stated: “We’re excited to introduce the SkyFan Turbo Heater, a breakthrough product that launches an entirely new category of heater-fans for our customers. This innovation brings year-round comfort and design together in a single solution, expanding the possibilities for how people heat, cool, and light their indoor and outdoor spaces.”

Rani Kohen, Founder and Executive Chairman of SKYX Platforms Corp., stated:
“We are experiencing great interest in our turbo heater and ceiling fan from both U.S. and global markets. This product exemplifies our commitment to innovation, safety, and global market products. As we prepare for our upcoming launch, we believe this all-in-one solution will drive significant value for our customers, partners, and shareholders.”

To view a video of SKYX’s turbo heater ceiling fan Click here.

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contact:
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/1e0bdf3b-8407-451e-8299-e784a510c37b

https://www.globenewswire.com/NewsRoom/AttachmentNg/1ed9980a-f8a3-4df6-9347-bd0d7c48d74f

https://www.globenewswire.com/NewsRoom/AttachmentNg/ed5a590d-d47e-4db5-9088-534a9ad833f

Release – V2X Wins $980 Million IDIQ Contract to Support Global Warfighter Test Systems

Posted on December 3, 2025December 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VVX

December 03, 2025

Download(opens in new window)

RESTON, Va., Dec. 3, 2025 /PRNewswire/ — V2X, Inc. (NYSE: VVX) has been awarded a position on the Automated Test Systems Division’s (ATS) Multiple Award indefinite delivery, indefinite quantity (IDIQ) contract by the Air Force Life Cycle Management Center at Warner Robins Air Force Base in Georgia.

V2X will provide rapid, full lifecycle support for ATS used to sustain critical warfighter operations worldwide. These systems support a wide array of aircraft platforms, including fighter jets, bombers, cargo/airlift/tanker aircraft, unmanned aerial vehicles, and helicopters. Users include the U.S. Air Force, Air Force Reserve, Air National Guard, F-35 Joint Strike Fighter program, Foreign Military Sales customers, amongst others.

“This award reflects our team’s continued commitment to delivering mission-critical solutions that supports operational readiness,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. “We are honored to contribute to the sustainment of vital test systems supporting the U.S. and allied partners around the world.”

The IDIQ contract provides flexible support for both legacy and future ATS requirements, with a base ordering period of five years and an option to extend for an additional five years. V2X will maintain and sustain both commercial and noncommercial products across the ATS Division’s portfolio.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-wins-980-million-idiq-contract-to-support-global-warfighter-test-systems-302628187.html

SOURCE V2X, Inc.

Release – Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Posted on December 3, 2025December 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GLSI

Download as PDF

December 03, 2025 6:00am EST

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01.

Flamingo-01 Progress to Date

The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the equivalent of 600 patients per year in approximately 40 US sites and 100 EU sites for a total of 140 active sites. The Company is considering a strategy to continue enrolling in both the HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted and the appropriate size of each arm can be further assessed.

CEO Snehal Patel commented, “Reaching 1,000 screened patients confirms that the interest from doctors and patients is high. The clinical site start-up activities in Europe in 2025 have further increased the momentum in the study. We are also receiving interest from other countries to join FLAMINGO-01, driven by patient interest. The high screening rate will give the Company many options, including the opportunity to continue enrollment through multiple interim analyses, the potential to realize higher enrollment rates and event rates, and the potential to maximize indications by analyzing efficacy across multiple HLA types in larger patient populations.”

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com

Source: Greenwich LifeSciences, Inc.

Released December 3, 2025

CoreCivic Announces Expansion of Revolving Credit Facility By $300 Million

Posted on December 2, 2025December 2, 2025 by slightbourne@noblecapitalmarkets.com

December 2, 2025

BRENTWOOD, Tenn., Dec. 02, 2025 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic” or the “Company”) announced today that it has entered into a First Amendment to its Fourth Amended and Restated Credit Agreement to, among other things, increase the size of the “accordion” feature that provides for uncommitted incremental extensions of credit from $200 million to $300 million, and to exercise the full allotment by expanding the capacity under the Revolving Credit Facility from $275 million to $575 million effective December 1, 2025 (the “Amendment”). The Company currently has outstanding borrowings under the Revolving Credit Facility of $165.0 million. Including outstanding letters of credit of $18.6 million and following the Amendment, the Company currently has additional borrowing capacity of $391.4 million.

David M. Garfinkle, CoreCivic’s Chief Financial Officer, commented, “As expressed on our last earnings call, with recent contract awards the Company is forecasting significant increases in revenues and cash flows going into 2026 and 2027. Expanding the size of our Revolving Credit Facility provides us with enhanced balance sheet flexibility while remaining positioned for strategic investments and long-term value creation, such as through our recently expanded buyback authorization.” Garfinkle continued, “I would like to thank the banks that participate in our bank credit facility. We are pleased to have such supportive banking relationships.”

Century Lithium Achieves High Recovery Of Rare Earth And Critical Elements From Primary Leach Solutions

Posted on December 2, 2025December 2, 2025 by slightbourne@noblecapitalmarkets.com

December 2, 2025 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to report positive results from its ongoing test work on the recovery of rare earth elements (“REEs”) from primary lithium leach solutions generated from its 100%-owned Angel Island lithium project in Nevada, USA. The initial testing indicates that high REE recoveries can be achieved without impacting lithium recovery in Century Lithium’s extraction process.

“The REE recovery results validate our belief that Century Lithium’s leach solutions offer meaningful secondary-value opportunities,” said Todd Fayram, Century Lithium’s Senior Vice President, Metallurgy. “Producing a secondary REE-rich product has the potential to strengthen Angel Island’s economics and align the Company with broader government and industry initiatives supporting secure North American critical-minerals supply chains.”

Century Lithium previously confirmed that the leach solutions produced from Angel Island claystone contain notable concentrations of REEs, including dysprosium, gadolinium, neodymium, and praseodymium, as well as higher concentrations of the critical metals scandium, lanthanum, and cerium. Cesium is also present.

Ion-exchange test work achieved greater than 97% recovery of the identified REEs and critical metals, excluding cesium, while maintaining complete selectivity against lithium. This selectivity is essential for downstream lithium recovery through the Company’s process flowsheet, which includes ultrafiltration, direct lithium extraction (“DLE”) and subsequent steps to produce high-purity lithium carbonate.

The Company’s metallurgical program at Angel Island continues to focus on the following: Optimizing ion-exchange performance and selectivity Advancing downstream processing flowsheets for REE concentration and refinement Evaluating market pathways for a commercial REE by-product Assessing the economic contribution of REEs to primary lithium production These results represent a significant technical milestone, demonstrating that REE extraction and recovery can be implemented without affecting the Company’s core lithium recovery process. Century Lithium believes these advancements position the Company to potentially supply both lithium and REEs to North American critical minerals markets, supporting supply-chain resilience and enhancing long-term project value for Angel Island

ISG to Evaluate Snowflake Ecosystem Partners

Posted on December 2, 2025December 2, 2025 by slightbourne@noblecapitalmarkets.com

12/2/2025

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining provider capabilities within the fast-growing Snowflake services ecosystem.

The study results will be published in a comprehensive ISG Provider Lens^® report, called Snowflake Ecosystem Partners, scheduled to be released in June 2026. The report will cover companies offering Snowflake-focused modernization and AI and ML enablement capabilities, along with ongoing managed data and optimization services.

Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm’s buy-side clients.

Snowflake has emerged as a critical data platform that redefines how enterprises store, process and activate data for analytics and AI. Its cloud-native architecture offers improved scalability, flexibility and cost efficiency, helping enterprises move beyond the constraints of traditional data warehouses. Globally, enterprises are increasingly adopting this platform to unify structured, semi-structured and unstructured data under a single governance and security model. This approach streamlines complex data operations while enabling faster insights and AI-driven innovation.

“Enterprises are prioritizing providers that offer automation maturity, FinOps discipline and robust governance,” said Aman Munglani, senior director and principal analyst at ISG. “Using Snowflake-native tools such as Snowpark, Cortex AI and Native Apps enables them to achieve meaningful, measurable improvements in data management.”

ISG has distributed surveys to more than 100 Snowflake ecosystem partners. Working in collaboration with ISG’s global advisors, the research team will produce two quadrants representing the Snowflake offerings the typical enterprise is buying, based on ISG’s experience working with its clients. The two quadrants are:

Modernization and AI/ML Enablement Services, evaluating providers that deliver end-to-end strategy, advisory and implementation support to help enterprises get the most from their Snowflake investments. These providers are assessed on their ability to guide data modernization efforts and facilitate integration of AI and ML into operations.
Managed Data and Optimization Services,assessing providers offering management, monitoring and optimization services for Snowflake environments. These providers should specialize in managing Snowflake infrastructure across cloud platforms and offer training and change management initiatives.

Geographically focused reports from the study will cover the global Snowflake ecosystem and examine products and services available worldwide. ISG analysts Gowtham Kumar Sampath and Hemangi Patel will serve as authors of the report.

A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as Snowflake ecosystem partners can contact ISG and ask to be included in the study.

All 2025 ISG Provider Lens^® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG’s continuous CX research.

About ISG Provider Lens^® Research

The ISG Provider Lens^® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Mistral Unveils New AI Models as Europe’s Rising Lab Races to Keep Pace with OpenAI and Google

Posted on December 2, 2025December 2, 2025 by slightbourne@noblecapitalmarkets.com

French artificial intelligence startup Mistral has introduced a new suite of advanced AI models, marking its most ambitious step yet as it races to remain competitive with global heavyweights like OpenAI, Google, and DeepSeek. The release comes at a pivotal moment in the AI ecosystem, where rapid innovation cycles and aggressive commercialization strategies are reshaping the landscape.

Mistral’s updated portfolio includes a new large multimodal model, which the company describes as the “world’s best open-weight multimodal and multilingual.” Designed for enterprise-grade performance, this model targets use cases such as AI assistants, scientific workloads, retrieval-augmented generation (RAG) systems, and complex agentic workflows. By pushing for open-weight access, Mistral continues to position itself as a key proponent of transparent and customizable AI—an increasingly important stance among European enterprises wary of closed-source dominance from U.S. labs.

Alongside the flagship model, the company launched Ministral 3, a compact, highly efficient model engineered for robotics, autonomous drones, consumer devices, and on-device intelligence. Its smaller footprint allows it to run on a single GPU, reducing operational costs and making it attractive for companies seeking scalable, low-latency AI without heavy cloud dependency. According to Mistral, smaller models offer major advantages in real-world applications, where speed, cost efficiency, and domain-specific tuning outperform size alone.

The launches build on a year of rapid growth for the Paris-based startup. Founded in 2023, Mistral raised 1.7 billion euros in September, reaching a valuation of 11.7 billion euros. The round was led by global semiconductor leader ASML, which invested 1.3 billion euros, with additional backing from Nvidia, Microsoft, and Andreessen Horowitz. This massive inflow of capital reflects Europe’s mounting urgency to develop AI champions capable of competing with U.S. and Chinese giants.

Mistral’s momentum extends beyond research. On Monday, the company announced a major commercial agreement with HSBC, granting the global bank access to its models for tasks such as financial forecasting, language translation, and automation. The startup has already secured additional enterprise contracts worth hundreds of millions of dollars, signaling growing trust from large organizations seeking alternatives to entrenched U.S. players.

Still, the competitive backdrop is intense. Rivals such as Anthropic and OpenAI are aggressively expanding into Europe, opening new offices and securing colossal funding rounds that dwarf those of European firms. With Anthropic now valued at $183 billion and OpenAI reportedly priced at nearly $500 billion through secondary sales, Mistral faces an uphill battle to match the scale of global rivals.

Nonetheless, the company maintains that the next era of AI will be defined not only by size, but by speed, adaptability, on-device intelligence, and openness. With its new models, Mistral aims to position itself at the forefront of this shift—advancing its vision of a globally distributed AI ecosystem that blends cutting-edge research with practical enterprise deployment.

Amazon Unveils New Trainium3 AI Chip as Big Tech Ramps Up Efforts to Challenge Nvidia’s Dominance

Posted on December 2, 2025December 2, 2025 by slightbourne@noblecapitalmarkets.com

Amazon has introduced its newest AI semiconductor, Trainium3, signaling another major push by tech giants to loosen Nvidia’s grip on the rapidly growing artificial intelligence hardware market. Announced Tuesday during Amazon Web Services’ annual re:Invent conference, the chip represents a significant leap in the company’s strategy to build affordable, high-performance computing infrastructure tailored for AI training and inference.

According to AWS, servers outfitted with Trainium3 deliver four times the speed and energy efficiency of the previous generation. For enterprises racing to scale large language models and multimodal systems, this improvement translates to faster development cycles and noticeably lower operational costs—an increasingly critical advantage as AI workloads explode.

“Trainium already represents a multibillion-dollar business today and continues to grow really rapidly,” said AWS CEO Matt Garman, underscoring Amazon’s deepening investment in custom silicon. Once primarily dependent on Nvidia for its cloud AI capacity, AWS now sees homegrown hardware as essential both for performance control and long-term cost stability.

Amazon is far from alone. The industry has entered a new era in which Nvidia’s largest customers—Google, Microsoft, Meta, and Amazon itself—are designing their own AI chips to reduce reliance on the GPU leader. In early November, Google debuted its Ironwood TPU v7, and reports suggest the company is negotiating a multibillion-dollar deal to supply TPUs to Meta. Meanwhile, Microsoft continues to develop its in-house silicon despite encountering delays.

AWS executives view this diversification as healthy for the broader ecosystem. “Diversity of chips in the AI market is a good thing,” said Dave Brown, AWS vice president of compute and machine learning, in an interview with Yahoo Finance. Brown emphasized that the rising demand for AI infrastructure is creating room for multiple architectures to coexist, each optimized for different workloads.

Cost remains one of Amazon’s sharpest competitive angles. Brown noted that developers using Trainium-based instances typically see 30% to 40% savings compared to Nvidia GPU clusters. At a time when AI model training can reach hundreds of millions—or even billions—of dollars, these savings could shift market dynamics.

Amazon is also expanding its AI infrastructure at massive scale. The company recently completed Project Rainier, a colossal data center initiative built specifically for AI workloads. OpenAI competitor Anthropic is expected to use one million of Amazon’s custom chips across Rainier and other AWS data centers by the end of 2025. Anthropic has reportedly played a hands-on role in guiding the chip’s design.

Still, Nvidia remains unmatched in both raw performance and software ecosystem maturity. CEO Jensen Huang has argued that developers would choose Nvidia chips “even if alternatives were free,” citing CUDA and the extensive tools built around Nvidia hardware. Amazon itself remains one of Nvidia’s biggest customers, accounting for 7.5% of Nvidia’s revenue, and OpenAI recently signed a $38 billion agreement to access Nvidia GPUs through AWS.

Yet Amazon is preparing for a future where its chips coexist seamlessly with Nvidia’s. The company revealed that its upcoming Trainium4 processors will support NVLink Fusion, Nvidia’s advanced networking technology that links chips across server racks. That compatibility signals a hybrid future—one where Amazon tightens control over its hardware roadmap while still acknowledging Nvidia as the industry’s gold standard.

Release – MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

Posted on December 1, 2025December 1, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

December 01, 2025 9:17am EST Download as PDF

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06.

Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares in the open market at an average price of $1.04 per share.

“Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date, we believe in ateganosine’s potential to improve the lives of patients diagnosed with non-small cell lung cancer and become a new standard of care.”

“I firmly believe MAIA’s cancer-therapy platform can redefine the landscape of cancer research and treatment,” said Mr. Luput. “As a longtime investor, I believe the company’s strategic focus and scientific momentum position it to deliver significant value for shareholders in the years ahead,” added Mr. Smith.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released December 1, 2025